in vivo News and Research

RSS

Advances in use of stem cells for tissue regeneration

A major issue in the development of regenerative medicine is the cell sources used to rebuild damaged tissues.

7 Nov 2008

Scientists identify compounds for stem-cell production from adult cells

In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects.

6 Nov 2008

Just one mutated SMAD4 allele is enough to cause cancer

Tumour suppressor genes do not necessarily require both alleles to be knocked out before disease phenotypes are expressed.

4 Nov 2008

Seeing nanotubes targeting tumors in vivo

Carbon nanotubes have significant potential for delivering both imaging and therapeutic agents to tumors, but there is still a need to better quantify how well these rolled-up sheets of graphite can target tumors.

27 Oct 2008

Near-infrared nanoparticles shine a bright light on cancer

A new nanoparticle-enabled imaging method for breast cancer has been developed by a team of scientists from Penn State. Their research, utilizing encapsulated fluorescent molecules in calcium phosphate nanoparticles and nontoxic near infrared (NIR) imaging, appears in the journal ACS Nano.

27 Oct 2008

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

26 Oct 2008

Nicotine linked to breast cancer growth and spread

A study published in Cancer Research, a journal of the American Association for Cancer Research, suggests a possible role for nicotine in breast tumor development and metastases.

15 Oct 2008

Kinaxo partners with Boehringer Ingelheim

Kinaxo Biotechnologies GmbH announced today that it has entered into a two-year collaboration with Boehringer Ingelheim. Under the agreement Kinaxo will apply its new platform technologies to studies on drug mode of action and target identification. Financial details of the agreement were not disclosed.

13 Oct 2008

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

Targeted nanoparticles map tumor blood supply in 3-D, assess therapy

One of the defining characteristics of solid tumors is the development of a network of new blood vessels to nourish the rapidly reproducing malignant cells. Now, using a nanoparticle targeted to those new blood vessels, a joint academic-industrial research team, led by investigators from the Siteman Center of Cancer Nanotechnology Excellence, has developed a way to construct a three-dimensional (3-D) map of tumor-induced angiogenesis and monitor the effects of drug therapies on those new blood vessels.

28 Sep 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Multifunctional polymer nanoparticles pass critical in vivo test

In an effort to overcome the drug resistance that often occurs in cancer, a team of investigators has developed a nanoparticle made of a blend of polymers that first releases a powerful anticancer drug and then delivers an agent that tricks a drug-resistant cell into committing suicide. Now, tests in mice with human breast cancer have shown that these blended nanoparticles are effective in maintaining high levels of both drugs in the vicinity of tumors.

28 Sep 2008

Anticancer drug triggers nanoparticle formation, improves stability in vivo

Paclitaxel is a powerful anticancer agent used to treat a variety of malignancies, but severe side effects limit its ultimate effectiveness and utility. To improve this drug's pharmacological properties, researchers have turned to nanoparticle-based delivery agents, although with marginal success; stably trapping large amounts of paclitaxel in most nanoparticles has proven difficult.

28 Sep 2008

Array BioPharma presents positive data on its glucokinase activators in type 2 diabetes

Array BioPharma Inc. has announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.

25 Sep 2008

S*BIO initiates trials of oral JAK2 inhibitor for hematological malignancies

S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma.

17 Sep 2008

Scientists develop nanometer-sized 'cargo ships' to target and destroy tumors

Scientists have developed nanometer-sized 'cargo ships' that can sail throughout the body via the bloodstream without immediate detection from the body's immune radar system and ferry their cargo of anti-cancer drugs and markers into tumors that might otherwise go untreated or undetected.

11 Sep 2008

MorphoSys announces publication of first MOR103 data

MorphoSys AG announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".

2 Sep 2008

Atomic bomb's effect results in adult-onset thyroid cancer

Radiation from the atomic bomb blasts in Hiroshima and Nagasaki, Japan, in 1945, likely rearranged chromosomes in some survivors who later developed papillary thyroid cancer as adults, according to Japanese researchers.

1 Sep 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Novel imaging reagents and technology that non-invasively locates, quantifies specific cells in the body

Magnetic resonance imaging (MRI) isn't just for capturing detailed images of the body's anatomy. Thanks to novel imaging reagents and technology developed by Carnegie Mellon University scientist Eric Ahrens, MRI can be used to visualize - with "exquisite" specificity - cell populations of interest in the living body. The ability to non-invasively locate and track cells, such as immune cells, will greatly aid the study and treatment of cancer, inflammation, and autoimmune diseases, as well as provide a tool for advancing clinical translation of the emerging field of cellular regenerative medicine, by tracking stem cells for example.

21 Aug 2008